Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Deucravacitinib in Paradoxical Psoriasis
NCT06281106Phase 3
Key facts
- Status
- Terminated
- Start
- Jun 2024
- Primary completion
- Mar 2025
- Countries
- 1
- Modality
- Small Molecules
- Drugs
- deucravacitinib
- Conditions
- psoriasis
01
Overview
Phase 3, randomised, double-blind trial in psoriasis comparing Deucravacitinib with Placebo (2 arms). Primary endpoint: Paradoxical Psoriasis Investigator Global Assessment at 4 weeks. Started Jun 2024; status: terminated.
02
Design
2 arms- Study design
- RandomizedDouble-blind
Deucravacitinib
Deucravacitinib 6mg oral intake once daily
Placebo
Matching Placebo oral intake once daily
03
Who it enrols
Patients with clinical diagnosis of Paradoxical Psoriasis caused by anti-TNF treatment, IGA >= 2, BSA >= 2%. Excludes active infections, malignancy within 5 years, and pregnancy.
04
Endpoints
Primary
Paradoxical Psoriasis Investigator Global Assessment
Secondary
Paradoxical Psoriasis Body Surface Area
Paradoxical Psoriasis palmoplantar Psoriasis Area and Severity Index
Paradoxical Psoriasis Scalp Investigator General Assessment
Psoriasis Area and Severity Index
American College of Rheumatology Score
Beyond the preview
Go deeper on NCT06281106.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06281106.